PLUS1
41.11
-0.02 (-0.05%)
-0.02 (-0.05%)
Upgrade to Real-Time
Regular Market
Best deals to access real time data! |
|
CHART Trader
Monthly Subscription
for only
|
|
Canadian Level 1 + USA
Monthly Subscription
for only
|
|
Small Cap Basic
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Sage Therapeutics Inc | SAGE | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Low Price | High Price | Open Price | Previous Close | Last Traded  |
|
|---|---|---|---|---|---|---|---|---|
| -0.02 | -0.05% | 41.11 | 40.66 | 42.58 | 41.51 | 41.13 | 10:23:12 |
| Bid Price | Ask Price | Spread | Spread % | News | |
|---|---|---|---|---|---|
| 41.11 | 41.20 | 0.09 | 0.22% | - | - |
| Stock Trades | Traded Volume | VWAP | Dollar Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 2,517 | 314,253 | $ 41.57 | $ 13,064,749 | 863,503 | 25.01 - 190.78 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 10:23:13 | 11 | $ 41.20 | USD |
Sage Therapeutics Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 2.13B | 51.92M | 37.56M | $ 6.87M | $ - | -13.38 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | 0.00% | 4.01k | 1.80% |
Sage Therapeutics News
| Date | Time | Source | News Article |
|---|---|---|---|
| 6/11/2020 | 16:22 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
| 6/11/2020 | 16:19 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
| 6/11/2020 | 16:19 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
| 6/11/2020 | 16:19 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
| 6/11/2020 | 16:19 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
| 6/11/2020 | 16:18 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
| 6/01/2020 | 06:30 | Business Wire | Sage Therapeutics to Present at Goldman Sachs 41st Annual.. |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical SAGE Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 41.67 | 44.91 | 40.66 | 42.97 | 595,143 | -0.56 | -1.34% |
| 1 Month | 38.01 | 44.91 | 37.2167 | 41.71 | 769,629 | 3.10 | 8.16% |
| 3 Months | 33.78 | 44.91 | 33.08 | 38.44 | 933,301 | 7.33 | 21.7% |
| 6 Months | 74.29 | 79.9357 | 25.01 | 41.54 | 1,060,944 | -33.18 | -44.66% |
| 1 Year | 190.15 | 190.78 | 25.01 | 66.72 | 891,210 | -149.04 | -78.38% |
| 3 Years | 81.08 | 195.97 | 25.01 | 104.01 | 667,984 | -39.97 | -49.3% |
| 5 Years | 73.55 | 195.97 | 25.01 | 85.28 | 601,653 | -32.44 | -44.11% |
Sage Therapeutics Description
| Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the study of the nervous system and brain to discover medicines to treat life-threatening, rare central nervous system disorders. The company's lead development program is SAGE-547, it is in Phase 3 clinical trials for super-refractory status epilepticus; and the SAGE-217 program which is in Phase 2 clinical trials for post-partum depression, essential tremor, Parkinson's disease and major depressive disorder. The company is also developing several other compounds for treatment that is in the early stage of development. |
